J Korean Neuropsychiatr Assoc. 2015 Feb;54(1):127-131. Korean. Published online February 28, 2015. https://doi.org/10.4306/jknpa.2015.54.1.127 | |
Copyright © 2015 Korean Neuropsychiatric Association |
Jung-Young Kim, MD,1,2
Nam-In Kang, MD, PhD,2
and Jong-Chul Yang, MD, PhD![]() | |
1Department of Psychiatry, Chonbuk National University Medical School, Jeonju, Korea. | |
2Department of Psychiatry, Jeonbuk Provincial Maeumsarang Hospital, Wanju, Korea. | |
3Research Institute of Clinical Medicine of Chonbuk National University-Biomedical Research Institute of Chonbuk National University Hospital, Jeonju, Korea. | |
![]() | |
Received December 19, 2014; Revised December 27, 2014; Accepted December 30, 2014. | |
Abstract
| |
Kleptomania is a well-known impulse-control disorder. Although it is a rare disease, it exerts a greater influence on the social and economic. There are a variety of treatments for kleptomania, however case reports of its specific treatment techniques are extremely rare. In this case, covert sensitization was applied to a 44-year-old hospitalized patient with kleptomania, which can facilitate a specific treatment method through case presentation. |
Keywords: Kleptomania; Covert sensitization; Cognitive behavior therapy |
Notes
|
The authors have no financial conflicts of interest.
References
|
1. | American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington, DC: American Psychiatric Association; 2013. |
2. | Goldman MJ. Kleptomania: making sense of the nonsensical. Am J Psychiatry 1991;148:986–996. |
3. | Grant JE, Kim SW. Clinical characteristics and associated psychopathology of 22 patients with kleptomania. Compr Psychiatry 2002;43:378–384. |
4. | Koran LM, Aboujaoude EN, Gamel NN. Escitalopram treatment of kleptomania: an open-label trial followed by double-blind discontinuation. J Clin Psychiatry 2007;68:422–427. |
5. | Grant JE, Kim SW, Odlaug BL. A double-blind, placebo-controlled study of the opiate antagonist, naltrexone, in the treatment of kleptomania. Biol Psychiatry 2009;65:600–606. |
6. | Grant JE. Understanding and treating kleptomania: new models and new treatments. Isr J Psychiatry Relat Sci 2006;43:81–87. |
7. | Grant JE, Potenza MN. Impulse control disorders: clinical characteristics and pharmacological management. Ann Clin Psychiatry 2004;16:27–34. |
8. | Grant JE, Odlaug BL. [Kleptomania: clinical characteristics and treatment]. Rev Bras Psiquiatr 2008;30 Supple 1:S11–S15. |
9. | Grant JE, Odlaug BL, Davis AA, Kim SW. Legal consequences of kleptomania. Psychiatr Q 2009;80:251–259. |
10. | Presta S, Marazziti D, Dell'Osso L, Pfanner C, Pallanti S, Cassano GB. Kleptomania: clinical features and comorbidity in an Italian sample. Compr Psychiatry 2002;43:7–12. |
11. | Fishbain DA. Kleptomania as risk-taking behavior in response to depression. Am J Psychother 1987;41:598–603. |
12. | McElroy SL, Pope HG Jr, Hudson JI, Keck PE Jr, White KL. Kleptomania: a report of 20 cases. Am J Psychiatry 1991;148:652–657. |